SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Astellas Pharma Inc. (ALPMY) News

Follow Astellas Pharma Inc. (ALPMY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ALPMY Asset equity Sector Markets 90 days 1 Last 17.2 Updated Oct 28, 2026, 08:35 AM UTC Open live news feed Open ALPMY chart & news
M Astellas Secures Option for Audax DAX-044 in Deal Worth Up to $1.34 Billion Astellas Pharma entered an exclusive option and license agreement for Audax Biosciences' DAX-04. MNA | Oct 28, 2026, 08:35 AM UTC L Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC Pfizer (PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda or Keytruda QLEX as neoadj COMMODITIES | Jul 10, 2026, 03:26 PM UTC H SGMO Files Chapter 11 Sangamo Therapeutics files for Chapter 11 bankruptcy protection and agrees to sell assets to Eli Lilly and Astellas Pharma EQUITY | Jun 23, 2026, 05:48 PM UTC